Danazol for unexplained subfertility

Systematic review / meta-analysis OA: closed CC0 ⤵ 8 in-corpus citations
⚙ AI-generated summary by gemini-2.5-flash-lite, 2026-07-09 ⓘ

Two trials involving 71 women found no statistically significant difference in live birth rates between danazol and placebo for unexplained subfertility, despite more pregnancies during follow-up and significant side effects.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

⚙ AI-generated deep summary by qwen3.7-flash, 2026-11-20 · read from full text ⓘ

This Cochrane review evaluated two randomized trials involving seventy-one women with unexplained subfertility to determine if danazol improves live birth rates compared to placebo. The analysis found no statistically significant difference in ongoing pregnancy or live birth outcomes between the treatment and control groups, although the drug was associated with significantly higher rates of menstrual irregularities and amenorrhoea. The authors concluded that due to the lack of efficacy and substantial adverse effects, including the need for contraception during therapy, danazol is unwarranted for treating unexplained subfertility. This paper is centrally about endometriosis — specifically noting that danazol was originally developed as a treatment for this condition before being tested for subfertility.

Read from the paper's body, not the abstract. Not a substitute for reading the paper. No clinical advice. How this works

Abstract

BACKGROUND: The synthetic androgen Danazol, was developed in the 1970's as a treatment for endometriosis. Its use was soon advocated in women with unexplained subfertility. Two randomised trials were subsequently conducted to assess the effectiveness of danazol in this population. OBJECTIVES: The objective of this review was to assess the effect of danazol on live birth rate in women with unexplained subfertility. SEARCH STRATEGY: We searched the Cochrane Menstrual Disorders and Sub-fertility Group's specialised register of trials (searched November , 2006) the Cochrane Register of Controlled Trials (The Cochrane Library, Issue 4, 2006), MEDLINE (1966-November 2006), EMBASE (1980 - November 2006) and reference lists of articles. SELECTION CRITERIA: Randomised trials of danazol compared with placebo or no treatment in women with unexplained subfertility. DATA COLLECTION AND ANALYSIS: Data were extracted by two reviewers EH and GT. MAIN RESULTS: Two trials involving seventy-one women were included. There was no statistically significant difference in the live birth/ ongoing pregnancy rate between danazol and placebo at the end of treatment (OR 1.16, 95% CI 0.0 to 8.29; P=0.36) or at the end of follow-up (OR 2.41; 95% CI 0.59, 9.82; P=0.22). There was no significant difference in clinical pregnancies following treatment (OR 0.14, 95% CI 0.01, 2.26; P=0.17), however there were significantly more clinical pregnancies during the follow-up period in the danazol group compared with the placebo group (OR 3.15, 95%CI 0.98, 10.10; P<0.05). Multiple side effects were reported. AUTHORS' CONCLUSIONS: Available data demonstrate no evidence of the benefit of danazol for unexplained subfertility. Although there is insufficient evidence to be certain of this, the need for contraception during treatment and the adverse effects and costs of danazol, make its use for this problem unwarranted. The increased pregnancy rate in the long term follow-up data may be attributable to additional therapies and did not influence the live birth/ongoing pregnancy data.
Full text 22,017 characters · extracted from oa-html · 11 sections · click to expand

Abstract

Background The synthetic androgen Danazol, was developed in the 1970's as a treatment for endometriosis. Its use was soon advocated in women with unexplained subfertility. Two randomised trials were subsequently conducted to assess the effectiveness of danazol in this population.

Objectives

The objective of this review was to assess the effect of danazol on live birth rate in women with unexplained subfertility. Search methods We searched the Cochrane Menstrual Disorders and Sub‐fertility Group's specialised register of trials (searched November , 2006) the Cochrane Register of Controlled Trials (The Cochrane Library, Issue 4, 2006), MEDLINE (1966‐November 2006), EMBASE (1980 ‐ November 2006) and reference lists of articles. Selection criteria Randomised trials of danazol compared with placebo or no treatment in women with unexplained subfertility. Data collection and analysis Data were extracted by two reviewers EH and GT. Main results Two trials involving seventy‐one women were included. There was no statistically significant difference in the live birth/ ongoing pregnancy rate between danazol and placebo at the end of treatment (OR 1.16, 95% CI 0.0 to 8.29; p=0.36) or at the end of follow‐up (OR 2.41; 95% CI 0.59 to 9.82; p=0.22). There was no significant difference in clinical pregnancies following treatment (OR 0.14, 95% CI 0.01 to 2.26; p=0.17), however there were significantly more clinical pregnancies during the follow‐up period in the danazol group compared with the placebo group (OR 3.15, 95%CI 0.98 to 10.10; p<0.05). Multiple side effects were reported. Authors' conclusions Available data demonstrate no evidence of the benefit of danazol for unexplained subfertility. Although there is insufficient evidence to be certain of this, the need for contraception during treatment and the adverse effects and costs of danazol, make its use for this problem unwarranted. The increased pregnancy rate in the long term follow‐up data may be attributable to additional therapies and did not influence the live birth/ongoing pregnancy data.

Keywords

Female; Humans; Danazol; Danazol/therapeutic use; Estrogen Antagonists; Estrogen Antagonists/therapeutic use; Infertility, Female; Infertility, Female/drug therapy Plain language summary Danazol for treating subfertility The drug danazol (Danocrine) was the most frequently prescribed medication for endometriosis but has also been tested as a treatment for unexplained subfertility. The review of trials found that there is no evidence that low doses of danazol improve live births/ ongoing pregnancy rates. Other negative factors include adverse effects.

Background

Danazol, a synthetic derivative of ethisterone, was originally developed as a treatment for endometriosis. It is administered as an oral tablet. Kennedy 1990 summarises that the possible modes of action for Danazol include direct effects on ovarian steroidogenesis (Olsson 1986;Steingold 1986), endometrial growth (Rose 1988), and testosterone displacement from sex hormone‐binding globulin; the suppression of which results in elevated free testosterone levels (Nilsson 1983). Danazol induced ovarian suppression results in amenorrhoea, endometrial atrophy and improvement in endometriotic lesions. It does however have anabolic and androgenic side effects including weight gain, oily skin, hirsutism, acne (Burry 1989) and hot flushes, depression, mood swings, changes in libido. The associated side effects prompted the term 'pseudomenopause' for the ovarian suppression resulting from danazol therapy (Dmowski 1976). Its use was advocated in women with unexplained infertility (Greenblatt 1974).

Objectives

The objective of this review was to test the hypothesis that danazol is more effective than placebo in the treatment of unexplained subfertility in terms of increasing the live birth/ongoing pregnancy rate.

Methods

Criteria for considering studies for this review Types of studies Only randomised trials were considered for inclusion, quasi randomised trials were excluded. Types of participants Participants were women with unexplained subfertility. Unexplained subfertility was defined as a duration of >1 year; tubal patency confirmed by hysterosalpingogram or laparoscopy; ovulation confirmed by a serum progesterone level considered to be in the ovulatory range by the authors, endometrial biopsy showing evidence of secretory change, or regular menstrual cycle of 21 to 42 days duration; semen quality considered normal based on acceptable standard at the time of publication. Types of interventions Oral danazol in any dose, compared with placebo or no treatment administered for any duration. Types of outcome measures Primary outcome measure was live birth/ongoing pregnancies per woman randomised and clinical pregnancies per woman randomised. Secondary outcome measures were spontaneous miscarriage, ectopic pregnancies and side effects. Search methods for identification of studies We searched for all publications which describe (or might describe) randomised controlled trials of danazol for unexplained sub‐fertility. The original search was performed in 1995 and updated in 1999, 2005 and 2006. Electronic searches 1) We searched the Cochrane Menstrual Disorders and Sub‐fertility Group's specialised register of trials (searched November, 2006). See review group details for more details on the make‐up of the Specialised Register. 2) The Cochrane Central Register of Controlled Trials (CENTRAL) on The Cochrane Library, Issue 4, 2006 was searched in all fields 3) The following electronic databases were searched using Ovid software using search string see Appendix 1 Searching other resources 4) The citation lists of relevant publications, review articles and included studies were also searched. Data collection and analysis S tudy selection The study selection was undertaken by two reviewers (EH and GT). The titles and abstracts of articles found in the search were screened by EH and GT, who discarded studies that were clearly ineligible. Then EH, and GT independently assessed whether the studies met the inclusion criteria, with disagreements resolved by discussion. Further information was sought from the authors where papers contained insufficient information to make a decision about eligibility. An updated search was conducted in November 2006 by JB. A ssessment of Methodological Quality The quality of all studies that were deemed eligible for the review were assessed independently by the two reviewers (EH and GT), any discrepancies were resolved by discussion. The quality of allocation concealment was graded as adequate (A), unclear (B), or inadequate (C), following the detailed descriptions of these categories provided by the Menstrual Disorders and Subfertility Review Group. D ata and extraction and analysis Data extraction was performed independently by the two reviewers (EH and GT). Discrepancies were resolved by discussion. For each included trial, information was collected regarding the location of the study, methods of the study, the participants (age range, eligibility criteria), the nature of the interventions, and data relating to the outcomes specified above. Where possible, missing data was sought from the authors. Statistical analysis was performed in accordance with the guidelines for statistical analysis developed by the Cochrane Collaboration. Heterogeneity (variations) between the results of different studies was examined by inspecting the scatter in the data points on the graphs and the overlap in their confidence intervals and, more formally, by checking the results of the chi‐squared tests. The I2 statistic for heterogeneity between groups was computed and used. Where possible, the outcomes were pooled statistically. For dichotomous data, results for each study were expressed as an odds ratio with 95% confidence interval and combined for meta‐analysis with RevMan software using the Peto method and a Fixed‐effect model.

Results

Description of studies Two small studies were identified (Iffland 1989; van Dijk 1979). van Dijk 1979 included forty women with unexplained subfertility, treating them with Danazol 200 mg or placebo, daily for one hundred days. During this time, contraception does not appear to have been advised, despite the potential adverse effects of danazol during early pregnancy. Follow up was for six months and only pregnancies occurring during that period were included in the analysis. Iffland 1989 included thirty‐nine women with primary unexplained subfertility. Treatment with Danazol 200 mg daily or placebo lasted for three months. Eight women were excluded from analysis because of failure to complete treatment or medical illness. Three further women were withdrawn from the Danazol group during the follow up phase, which lasted twelve months. Iffland 1989 reported that nineteen women underwent additional therapies including superovulation, intrauterine artificial insemination, IVF and embryo transfer or gamete intrafallopian transfer post study treatment. Risk of bias in included studies See Table 1. Neither of these studies explicitly stated the method of allocation nor randomisation method used. The high incidence of oligomenorrhoea associate with active treatment makes blinding virtually impossible. One study (van Dijk 1979) reported complete follow‐up among forty couples, but excluded one patient from the analysis (placebo group) because she conceived during the six month treatment phase, rather than in the six month post‐treatment period. This decision undermines the validity of their conclusions. This patient has been included as part of the intention‐to treat for the meta‐analysis. 1. Risk of bias table. | Study ID | Randomisation | Concealment | Power | Intent‐to Treat | Attrition | Funding | | Iffland 1989 | No details of randomisation method | No details of allocation concealment | No details | No details | Eight women excluded. Six failed to start or complete the treatment , 1 was diagnosed as a diabetic and 1 with hypothyroidism | Winthrop laboratories, UK | | Van Dijk 1979 | No details of randomisation method | No details of allocation concealment | No details | No details, 1 pregnancy in the placebo group during treatment was excluded from the analysis but has been included as the ITT population in this meta‐analysis | n=1, one woman was excluded due to pregnancy in the placebo group | No details | A second study [Iffland 1989] described the eight patients who left their trial post randomization, but did not report the pregnancy rate in this group. Interestingly, although side effects were reported with a similar frequency between groups in this study, more women left the Danazol than the placebo group, leaving eleven and seventeen women respectively. Neither trial used a crossover design and co‐intervention did not appear to be present. Effects of interventions Two trials involving seventy‐one women were included (Iffland 1989; van Dijk 1979). There was no statistically significant difference in the live birth/ ongoing pregnancy rate between Danazol and placebo at the end of treatment (OR 1.16, 95% CI 0.0 to 8.29; P=0.36) or at the end of follow‐up (OR 2.41; 95% CI 0.59, 9.82; P=0.22). There was no significant difference in clinical pregnancies following treatment (OR 0.14, 95% CI 0.01, 2.26; P=0.17), however there were significantly more clinical pregnancies during the follow‐up period in the Danazol group compared with the placebo group (OR 3.15, 95%CI 0.98, 10.10; P<0.05). Multiple side effects were reported by Iffland 1989 although no significant differences were observed between treatment and placebo groups. Menstrual irregularities were reported by both papers (Iffland 1989; van Dijk 1979) with significantly more women reporting menstrual irregularities and amenorrhoea in the Danazol group compared to placebo (OR13.60; 95%CI 4.96, 37.31; P<0.0001).

Discussion

These studies are limited by their small sample size and lack of methodological quality. The results indicated no evidence of benefit of Danazol over placebo on live births/ongoing pregnancies. The significant effect on clinical pregnancies in the long term follow up may be attributable to the use of additional therapies which women had undergone in that time period. The significant effect of menstrual irregularities is a treatment effect although the statistical heterogeneity in the studies is high (I2 = 77.9%). When the evidence of lack of treatment effect and the known adverse effects of Danazol, including weight gain, acne and hirsutism are considered, it is the authors opinion that Danazol cannot be recommended in women with unexplained subfertility. Authors' conclusions Implications for practice. There is no evidence of benefit of Danazol in women with unexplained subfertility. Implications for research. Larger trials do not appear to be warranted based on these findings. What's new | Date | Event | Description | |---|---|---| | 10 November 2008 | Review declared as stable | The MDSG feel that there are unlikely to be any further RCT's in this topic area and therefore this review was closed following its publication Issue 1,2007 | | 7 November 2008 | Amended | Converted to new review format. | History Protocol first published: Issue 1, 1996 Review first published: Issue 1, 1996 | Date | Event | Description | |---|---|---| | 15 November 2006 | New citation required and conclusions have changed | Substantive amendment | Notes The MDSG feel that there are unlikely to be any further RCT's in this topic area and therefore this review will be closed following its publication Issue 1,2007

Acknowledgements

The review authors wish to acknowledge the support of the MDSG for their help and support. Appendices Appendix 1. Search string MEDLINE (1966‐November 2006) EMBASE (1980 ‐ November 2006 ) 1 (unexplained adj3 infertil$).mp. 2 (unexplained adj3 subfertil$).mp. 3 (idiopathic adj3 infertil$).mp. 4 (idiopathic adj3 subfertil$).mp. 5 or/1‐4 6 danazol.mp. or exp DANAZOL/ 7 5 and 6 8 randomized controlled trial.pt. 9 controlled clinical trial.pt. 10 randomized controlled trials/ 11 random allocation/ 12 double‐blind method/ 13 single‐blind method/ 14 or/8‐13 15 clinical trial.pt. 16 exp clinical trials/ 17 (clin$ adj25 trial$).ti,ab,sh. 18 ((singl$ or doubl$ or tripl$ or trebl$) adj25 (blind$ or mask$)).ti,ab,sh. 19 placebos/ 20 placebo$.ti,ab,sh. 21 random$.ti,ab,sh. 22 research design/ 23 or/15‐22 24 animal/ not (human/ and animal/) 25 14 or 23 26 25 not 24 27 7 and 26 Data and analyses Comparison 1. Danazol versus placebo in unexplained subfertility. | Outcome or subgroup title | No. of studies | No. of participants | Statistical method | Effect size | |---|---|---|---|---| | 1 Live birth/ongoing pregnancies per woman randomised following treatment | 1 | 31 | Peto Odds Ratio (Peto, Fixed, 95% CI) | 0.16 [0.00, 8.29] | | 2 Live births/ongoing pregnancies per woman randomised during treatment and follow up | 2 | 71 | Peto Odds Ratio (Peto, Fixed, 95% CI) | 2.41 [0.59, 9.82] | | 3 Pregnancy per woman randomised following treatment | 2 | 71 | Peto Odds Ratio (Peto, Fixed, 95% CI) | 0.14 [0.01, 2.26] | | 4 Pregnancies per woman randomised during treatment and follow up | 2 | 71 | Peto Odds Ratio (Peto, Fixed, 95% CI) | 3.15 [0.98, 10.10] | | 5 Miscarriage per woman randomised | 1 | 31 | Peto Odds Ratio (Peto, Fixed, 95% CI) | 9.88 [0.58, 167.86] | | 6 Ectopic pregnancy per woman randomised | 1 | 40 | Peto Odds Ratio (Peto, Fixed, 95% CI) | 7.06 [0.42, 117.50] | | 7 Adverse events/side effects | 2 | Peto Odds Ratio (Peto, Fixed, 95% CI) | Subtotals only | | | 7.1 Skin changes | 1 | 31 | Peto Odds Ratio (Peto, Fixed, 95% CI) | 0.74 [0.17, 3.29] | | 7.2 Headache/migraine | 1 | 31 | Peto Odds Ratio (Peto, Fixed, 95% CI) | 0.15 [0.01, 2.58] | | 7.3 Abdominal bloating/discomfort | 1 | 31 | Peto Odds Ratio (Peto, Fixed, 95% CI) | 5.07 [0.76, 33.62] | | 7.4 Tender breasts | 1 | 31 | Peto Odds Ratio (Peto, Fixed, 95% CI) | 0.15 [0.01, 2.58] | | 7.5 Oligomenorrhea/amenorrhoea | 2 | 71 | Peto Odds Ratio (Peto, Fixed, 95% CI) | 13.60 [4.96, 37.31] | | 7.6 Weight gain | 1 | 31 | Peto Odds Ratio (Peto, Fixed, 95% CI) | 1.29 [0.26, 6.33] | | 7.7 Other reported side effects | 1 | 31 | Peto Odds Ratio (Peto, Fixed, 95% CI) | 0.38 [0.09, 1.56] | Characteristics of studies Characteristics of included studies [ordered by study ID] Iffland 1989. | Methods | Random allocation. Method not stated. No details of allocation concealment. Double blind design. Attrition was 8/39 see quality table for details. | | | Participants | UK study. 39 women with primary unexplained subfertility. Women were aged 20‐38, mean age Danazol group 30.8 +/‐ 3.3, placebo group 30.9 +/‐ 3.5 years. Inclusion criteria were for no known endocrine disorder, regular menstrual cycles, ovulating, normal laparoscopy at least 6 months prior to study entry, +ve post coital test. Normal semen analysis and no variocoele in male partner. No other details of exclusion. | | | Interventions | Danazol 200 mg daily for 12 weeks, n=14 patients vs Placebo one tablet daily for 12 weeks, n=17 patients Long term follow up for up to 36 months. | | | Outcomes | Pregnancy Haematologic and liver function tests Side effects | | | Notes | || | Risk of bias | || | Bias | Authors' judgement | Support for judgement | | Allocation concealment? | Unclear risk | B ‐ Unclear | van Dijk 1979. | Methods | Random allocation. Method not stated. No details of concealment. There was an attempt to blind the women to treatment allocation but investigators were aware of which treatment arm women were in as study progressed. Attrition was 1/40 see quality table for details. | | | Participants | Dutch study. Participants were 40 women with unexplained infertility (primary and secondary); BBT, luteal serum progesterone, HSG, normal semen, PCT. Median age of placebo group was 29.5 (range 26‐37), and of Danazol group was 30 (range 27‐38 years). Only women who had undergone laparoscopy at least 6 months earlier were included. | | | Interventions | Danazol 200 mg orally daily for 6 months, n=21 vs Placebo one tablet daily for 6 months, n=19 Women were followed up for six months at 2 monthly intervals. | | | Outcomes | Pregnancy FSH, LH, prolactin, estradiol, progesterone, side effects. | | | Notes | Author's analysis excludes 1 pregnancy in the placebo group; this has been included as ITT in this meta‐analysis. Follow‐up duration was 6 months | | | Risk of bias | || | Bias | Authors' judgement | Support for judgement | | Allocation concealment? | Unclear risk | B ‐ Unclear | Characteristics of excluded studies [ordered by study ID] | Study | Reason for exclusion | |---|---| | Need 1992 | Study of danazol for menorrhagia. Pregnancy data not recorded. | Differences between protocol and review The search has been revised Contributions of authors Julie Brown was involved in the most recent update of this review October 2006. She ran the latest electronic search and updated the style of the review to the the MDSG standards. Sources of support Internal sources Ministry of Health, New Zealand. External sources Royal Commission on New Reproductive Technologies, Not specified. Declarations of interest None known Stable (no update expected for reasons given in 'What's new')

References

References to studies included in this review Iffland 1989 {published data only} - Iffland CA, Shaw RW, Beynon JL. Is danazol a useful treatment in unexplained primary infertility?. European Journal Obstetric Gynecological Reproductive Biology 1989;32:115‐21. [DOI] [PubMed] [Google Scholar] van Dijk 1979 {published data only} - Dijk JG, Frolich M, Brand EC, Hall EV. The treatment of unexplained infertility with danazol. Fertility and Sterility 1979;31:481‐5. [DOI] [PubMed] [Google Scholar]

References

to studies excluded from this review Need 1992 {published data only} - Need JA, Forbes KL, Milazzo L, McKenzie E. Danazol in the treatment of menorrhagia: The effect of a 1 month induction dose (200 mg) and 2 month's maintenance therapy (200 mg, 100 mg, 50 mg or placebo). Australian New Z ealand Journal Obstetrics and Gynaecology 1992;32:346‐52. [DOI] [PubMed] [Google Scholar] Additional references Burry 1989 - Burry K, Patton P, Illingworth D. Metabolic changes during medical treatment of endometriosis: Nafarelin acetate versus danazol. American Journal of Obstetrics and Gynecology 1989;160(6):1454‐61. [DOI] [PubMed] [Google Scholar] Dmowski 1976 - Dmowski W, Scommegna A. The rationale for treatment of endometriosis with dananzol. In: Greenblatt R editor(s). Recent Advances in Endometriosis. Proceedings of a Symposium. Amsterdam. Excerpta Medica, 1976:99. [Google Scholar] Greenblatt 1974 - Greenblatt RB, Borenstein R, Ayup H. Experiences with danazol (an antigonadotrophin) in the treatment of infertility. American Journal Obstetrics and Gynecology 1974;118:783. [DOI] [PubMed] [Google Scholar] Kennedy 1990 - Kennedy S, Williams I, Brodribb J, Barlow D, Shaw R. A comparison of nafarelin acetate and danazol in the treatment of endometriosis. Fertility and Sterility 1990;53(6):998‐1003. [DOI] [PubMed] [Google Scholar] Nilsson 1983 - Nilsson B, Sodergard R, Damber M, Damber J, Schoultz B. Free testosterone levels during danazol therapy. Ferility and Sterility 1983;39:505. [DOI] [PubMed] [Google Scholar] Olsson 1986 - Olsson J, Hillensjo T, Nilsson L. Inhibitory effects of danazol on steroidogenesis in cultured human granulosa cells. Fertility and Sterility 1986;46:237. [PubMed] [Google Scholar] Rose 1988 - Rose G, Dowsett M, Mudge J, White J, Jeffcoate S. The inhibitory effects of danazol, danazol metabolites, gestrinone, and testosterone on the growth of human endometrial cells in vitro. Fertility and Sterility 1988;49:224. [DOI] [PubMed] [Google Scholar] Steingold 1986 - Steingold KA, Lu JKH, Judd HL, Meldrum DR. Danazol inhibits steroidogenesis by the human embryo in vivo. Fertility and Sterility 1986;45:649. [DOI] [PubMed] [Google Scholar]

Text is read by the "Ask this paper" AI Q&A widget below. Extraction quality varies by source — PMC NXML preserves structure cleanly, OA-HTML may include some navigation residue, and OA-PDF can have broken hyphenation. The publisher copy (via DOI) is the canonical version.

My notes (saved in your browser only)

⚙ Ask this paper AI returns verbatim quotes from the full text · source: oa-html ⓘ

Answers must be backed by verbatim quotes from this paper's full text. Hallucinated quotes are dropped automatically; if no verbatim passage answers the question, we say so. How this works

Condition tags

endometriosis

MeSH descriptors

Danazol Estrogen Antagonists Infertility, Female Danazol Danazol Estrogen Antagonists Estrogen Antagonists Female Female Humans Humans Infertility, Female Infertility, Female

Citation neighborhood (2-hop)

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. Outer rings show 2-hop neighbours — papers reached through the immediate citers/citees. [ collapse to 1-hop ]

References (10)

Cited by (7)

Source provenance

europepmc
last seen: 2026-11-22T06:15:05.045840+00:00
openalex
last seen: 2026-05-11T07:04:57.594281+00:00
pubmed
last seen: 2026-10-08T21:04:12.251519+00:00
unpaywall
last seen: 2026-10-31T06:28:23.984441+00:00
License: CC0 · commercial use OK